中文名 | N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
英文名 | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea |
别名 | 1-(4-((6,7-二甲基-4-基)氧基)-2-甲氧基苯基)-3-(1-(噻唑-2-基)乙基)脲 N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-2-甲氧基苯基]-N'-[1-(2-噻唑基)乙基]脲 |
英文别名 | KI20227 Ki20227 CS-1094 KI 20227 KI-20227 N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea 1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]- |
CAS | 623142-96-1 |
EINECS | 200-258-5 |
化学式 | C24H24N4O5S |
分子量 | 480.54 |
密度 | 1.327 |
沸点 | 621.8±55.0 °C(Predicted) |
闪点 | 329.846 °C |
酸度系数 | 12.03±0.46(Predicted) |
存储条件 | Sealed in dry,Store in freezer, under -20°C |
外观 | 棕色粉末。 |
体外研究 | Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively. Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. Cell Viability Assay Cell Line: M-NFS-60 cells, HUVEC cells, human A375 melanoma cells Concentration: 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time: 72 hours Result: 100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively. Cell Viability Assay Cell Line: RAW264.7 cell lysate Concentration: 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time: 1 hour Result: Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. |
体内研究 | Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice. Animal Model: 4-week-old male F344/NJcl-rnu rats Dosage: 10, 20, and 50 mg/kg Administration: Orally; once per day for 20 days Result: Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.081 ml | 10.405 ml | 20.809 ml |
5 mM | 0.416 ml | 2.081 ml | 4.162 ml |
10 mM | 0.208 ml | 1.04 ml | 2.081 ml |
5 mM | 0.042 ml | 0.208 ml | 0.416 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!